publication date: Mar. 31, 2016
Non-Small Cell Lung Cancer
Atezolizumab Immunotherapy Boosts OS Compared to Docetaxel in Phase II Trial
Patients with advanced metastatic lung cancer treated with atezolizumab, a targeted immunotherapy drug, lived significantly longer and with fewer side effects than those who received docetaxel chemotherapy, according to a study published in The Lancet.
“The results of this study demonstrate that the use of atezolizumab, a monoclonal antibody, improves the survival rate of a majority of lung cancer patients who have progressive cancer when used after first-line chemotherapy,” said lead author Louis Fehrenbacher, medical director of Kaiser Permanente Oncology Clinical Trials.
The phase II trial enrolled 287 patients in 13 countries between August 2013 and March 2014. All patients had metastatic non-small-cell lung cancer that had been previously treated with at least one course of chemotherapy. Genetic profiling of their tumors identified the immune-system protein PD-L1. Treatments were administered intravenously every 21 days, for as long as patients were receiving clinical benefits.
At 13 months of follow-up, patients receiving atezolizumab had an average overall survival of 12.6 months, compared to 9.7 months in the docetaxel arm. Twelve of those who received atezolizumab still had an ongoing response to the drug at that time, compared to five receiving docetaxel. At 20 months after the initiation of treatment, approximately twice as many people receiving atezolizumab survived.
Patients receiving the experimental drug were less likely to experience serious side effects than those receiving the standard chemotherapy drug, at 40.1 percent versus 52.6 percent, respectively.
Continue reading CCL March – Atezolizumab Immunotherapy Boosts OS Compared to Docetaxel in Phase II Trial
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.